Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibody-based therapies in oncology. The company entered public markets through a merger with Brookline Capital Acquisition Corp, a blank-check vehicle sponsored by Brookline Capital Markets that completed its IPO in 2021. Apexigen filed a Form 10-Q with the SEC on May 23, 2022, reflecting its status as a recently combined public entity operating in the biopharmaceutical and cancer immunotherapy sector. Its pipeline targets solid tumors and hematologic malignancies with next-generation immune-activating antibody candidates. Sign up on SpacDesk for full filing history, sponsor details, and real-time analytics on Apexigen and the broader SPAC universe.